exhibit 99
================================================================================
================================================================================
FONAR CORPORATION
*
For Immediate Release FONAR Corporation NASDAQ-FONR
Contact: Daniel Culver 110 Marcus Drive
Director of Communications Melville, New York 11747
Web site: www.fonar.com Telephone: (631) 694-2929
Email: investor@fonar.com Fax Number: (631) 390-1709
================================================================================
FONAR ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL 2011
AS INCOME AND REVENUES ADVANCE
MELVILLE, NEW YORK, November 19, 2010 - FONAR Corporation (NASDAQ-FONR), The
Inventor of MR Scanning(TM), today announced its earnings for the first quarter
of fiscal 2011, ending September 30, 2010.
Income from operations for the quarter ending September 30, 2010 was $435,000 as
compared to a loss of $1,422,000 for the same period one year earlier, ending
September 30, 2009. FONAR has had income from operations for three quarters in a
row.
Net income for the first quarter of fiscal 2011 ending September 30, 2010 was
$385,000 as compared to a net loss of $1.7 million for the same quarter one year
earlier ending September 30, 2009.
Total net revenues for the quarter ending September 30, 2010 increased 16% to
$8.7 million as compared to the one year earlier to the quarter ending September
30, 2009, when net revenues were $7.5 million.
Within the revenue category, the management and other fees segment (management
of diagnostic imaging centers segment) increased 30% from $2.5 million for the
three-month period ending September 30, 2009, to $3.3 million for the three-
month period ending September 30, 2010. Total costs related to the management
and other fees segment increased just 1%, from $2.0 million for the three-month
period ending September 30, 2009, to $2.1 million for the three-month period
ending September 30, 2010.
The service and repair net fees were at $2.7 million, for the three-month period
ending September 30, 2010, as compared to the three-month period ending
September 30, 2009, one year earlier, when revenues were $2.8 million.
Total product sales (FONAR UPRIGHT(R) Multi-Position(TM) MRI scanners) increased
70% from $1.6 million for the three-month period ending September 30, 2009, to
$2.7 million for the three-month period ending September 30, 2010.
At the end of the first fiscal quarter of fiscal 2011 ending September 30, 2010,
total current assets were $15.3 million, total assets were $22.0 million, total
current liabilities were $25.0 million, total long-term liabilities were $2.2
million, and total cash, cash equivalents and marketable securities were $1.3
million.
Worldwide 147 FONAR UPRIGHT(R) Multi-Position(TM) MRI units have been installed
as of September 30, 2010.
Commenting on the results of the first quarter of fiscal 2011, Raymond Damadian,
M.D., president and chairman of FONAR said, "We are delighted to be able to show
rising income for the first quarter of fiscal 2011. This has largely been done
by cutting costs. Important savings have been made by reducing our Selling,
General and Administrative expenses and our Research and Development expenses.
In fact, these two categories have been reduced 31% when comparing the most
recent fiscal quarter ending September 30, 2010 with the first quarter of fiscal
2010 ending September 30, 2009."
"I am also pleased to announce that during the most recent fiscal quarter, FONAR
has installed its first UPRIGHT(R) Multi-Position(TM) MRI in Africa and
Australia making FONAR a true global participant in the MRI world," added Dr.
Damadian. We have installed 14 of our nearly 150 FONAR UPRIGHT(R)
Multi-Position(TM) MRI scanners outside of the United States."
HIGHLIGHTS OF THE FIRST QUARTER OF FISCAL 2011
The peer-reviewed, medical journal "Brain Injury," in its July, 2010 edition,
published a very significant study of 1200 neck pain patients comparing the
FONAR UPRIGHT(R) Multi-Position(TM) MRI to a conventional recumbent MRI and the
ability to diagnose whiplash trauma from a motor vehicle accident. The title of
the article is: `A case-control study of cerebellar tonsillar ectopia (Chiari)
and head/neck trauma (whiplash).'
The 1200 neck pain patients were divided into 4 groups, consisting of 2 control
neck pain groups that did not experience whiplash trauma and 2 neck pain groups
that did. The radiologists who read the study images were blinded as to which
images were the patient images and which were the control images. The patients
were examined in both the upright and recumbent positions. The recumbent MRI
images were obtained in a conventional recumbent MRI and the upright images were
obtained in the FONAR UPRIGHT(R) Multi-Position(TM)MRI.
The study, as presented in "Brain Injury," showed that the `fallen' cerebellar
tonsillar ectopia (CTE) caused by motor vehicle whiplash injuries was being
missed 60% of the time when the patient was scanned laying down in a
conventional recumbent-only MRI. The study reported that the whiplash injuries
were found when scanned upright in the FONAR UPRIGHT(R) Multi-Position(TM) MRI.
As a result of this study, the medical evidence indicates that the `fallen'
cerebellar tonsillar ectopias of a whiplash injury patient can now be reliably
visualized by using the FONAR UPRIGHT(R) Multi-Position(TM) MRI.
For more details, visit: (www.fonar.com/news/072110.htm). To obtain a copy of
the article published in the peer-reviewed journal, "Brain Injury," please
contact FONAR or use a Web search engine.
Soon after the publication in "Brain Injury," the Company announced the fourth
purchase of a FONAR UPRIGHT(R) Multi-Position(TM) MRI by Medserena, of Germany.
The CEO of Medserena, Matthias Schulz, said, "From our point of view, here in
Germany, the newly published 1200 patient study in `Brain Injury' sets a `new
standard of care' for whiplash injury patients."
Mr. Schulz continued, "The first three UPRIGHT(R) MRI centers have had great
success. With physicians all over Germany asking about this technology, it has
become imperative for us to expand and install a fourth UPRIGHT(R) scanner. This
is in spite of an intensely active MRI market in Germany, where there are
already many conventional lie-down MRIs installed. The large number of requests
coming from our physicians in Germany are arising because of the special medical
need for FONAR's unique technology."
"The German people have a long history in science and technology innovation,"
Mr. Schulz reported, "so we tend to recognize the potential of any new
technology quickly. We have been very successful in Germany with the FONAR
UPRIGHT(R) Multi-Position(TM) MRI and its power for scanning patients in
multiple upright and recumbent positions because our physicians have quickly
appreciated the benefits of this new technology and want their patients to have
access to those benefits as soon as possible. With 50% of MRIs being of the
spine, it is self-evident that to make a satisfactory imaging diagnosis of the
spine, the spine needs to be supporting its normal weight load which the
conventional lie-down MRI does not permit."
Mr. Schulz also said, "Automobile whiplash injuries are just as much a problem
in Germany as they are in any other industrialized nation. It was with great
pleasure that we learned of the July 2010 article in "Brain Injury," that will
now make it possible for physicians to visualize these injuries so that the most
expedient medical treatment can be provided. This is a huge advantage for the
FONAR UPRIGHT(R) Multi-Position(TM) MRI when it competes with other MRI
scanners."
NASDAQ NOTICE
On October 14, 2010, the Company received a notice of non-compliance from The
NASDAQ Stock Market, LLC., based upon the Company's non-compliance with the
minimum stockholders' equity requirement of $2.5 million for continued listing
on The NASDAQ Capital Market, as set forth in NASDAQ Marketplace Listing Rule
5550(b)(1)(the "Rule") (the "Stockholders' Equity Requirement"). The deficiency
was noted after the Company filed its Form 10-K on October 13, 2010, for the
Fiscal year ended June 30, 2010. In addition, the Company did not meet the
alternatives of market value of listed securities or net income from continuing
operations.
Under the Rules, the Company has 45 calendar days to submit a plan to regain
compliance. If the plan is accepted the NASDAQ Panel will grant an extension of
up to 180 calendar days from the date of the letter (October 14, 2010) to
evidence compliance. While the Company is hopeful that the Panel will grant its
request for continued listing on NASDAQ, there can be no assurance that the
Panel will do so.
MATTERS CONCERNING HOLDERS OF FONAR CORPORATION STOCK CERTIFICATES
Recently, many of our shareholders have received letters from CST (Computer
Share Trust), www.computershare.com, telephone 800-962-4284. It is very
important for investors to respond to these letters or else risk of being
subject to state escheatment laws. Essentially, shareholders holding older,
pre-reverse stock-split certificates must exchange their old certificates for
new ones.
In addition, investors may have changed addresses or appeared to have abandoned
their stock. If this could possibly be you, we urge you to contact CST to update
your information.
Again please call CST at 800-962-4284.
For more information on FONAR stock please visit: www.fonar.com/invest_faq.htm #
For investor and other information visit: www.fonar.com.
UPRIGHT(R) and STAND-UP(R) are registered trademarks and The Inventor of MR
Scanning(TM), Full Range of Motion(TM), pMRI(TM), Dynamic(TM),
Multi-Position(TM), True Flow(TM), The Proof is in the Picture(TM),
Spondylography(TM) Spondylometry(TM) and Upright Radiology(TM) are trademarks of
FONAR Corporation.
This release may include forward-looking statements from the company that may or
may not materialize. Additional information on factors that could potentially
affect the company's financial results may be found in the company's filings
with the Securities and Exchange Commission.
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
ASSETS September 30, June 30,
2010 2010
(UNAUDITED)
Current Assets: ----------- -------
Cash and cash equivalents $ 1,253 $ 1,299
Marketable securities 32 28
Accounts receivable - net 4,652 4,821
Accounts receivable - related parties - net 178 -
Medical receivables - net 12 25
Management fee receivable - net 2,593 2,569
Management fee receivable - related medical
practices - net 1,982 1,922
Costs and estimated earnings in excess of
billings on uncompleted contracts 1,225 277
Inventories 2,535 2,826
Advances and notes to related medical practices - net 42 83
Notes receivable - net 236 272
Prepaid expenses and other current assets 516 553
------ ------
Total Current Assets 15,256 14,675
------ ------
Property and equipment - net 1,981 2,109
Other intangible assets - net 4,190 4,291
Other assets 561 554
-------- --------
Total Assets $ 21,988 $ 21,629
======== ========
CONDENSED CONSOLIDATED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
(000's OMITTED)
LIABILITIES September 30, June 30,
2010 2010
(UNAUDITED)
Current Liabilities: ---------- --------
Current portion of long-term debt and
capital leases $ 590 $ 579
Current portion of long-term debt - related party 90 88
Accounts payable 2,855 3,192
Other current liabilities 9,512 8,065
Unearned revenue on service contracts 5,070 5,220
Unearned revenue on service contracts - related parties 165 -
Customer advances 5,366 4,813
Billings in excess of costs and estimated
earnings on uncompleted contracts 1,292 2,743
------ ------
Total Current Liabilities 24,940 24,700
Long-Term Liabilities:
Accounts payable 62 63
Due to related medical practices 228 528
Long-term debt & capital leases, less current portion 1,422 1,567
Long-term debt less current portion - related party 49 72
Other liabilities 484 475
------ ------
Total Long-Term Liabilities 2,245 2,705
------ ------
Total Liabilities 27,185 27,405
------ ------
CONDENSED CONSOLIDATED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
(000's OMITTED)
(Continued)
STOCKHOLDERS' DEFICIENCY:
Class A non-voting preferred stock $.0001 par value;
453,000 and 1,600,000 shares authorized at
September 30, 2010 and June 30, 2010, respectively;
313,451 issued and outstanding
at September 30, 2010 and June 30, 2010 - -
Preferred stock $.001 par value; 567,000 and
2,000,000 shares authorized at September 30, 2010
and June 30, 2010, respectively;
issued and outstanding - none - -
Common Stock $.0001 par value; 8,500,000 and 30,000,000
shares authorized at September 30, 2010 and June 30, 2010,
respectively; 5,112,458 and 4,985,850 issued at
September 30, 2010 and June 30, 2010, respectively;
5,100,815 and 4,974,207 outstanding at September 30, 2010
and June 30, 2010, respectively 1 1
Class B Common Stock $ .0001 par value; 227,000 and
800,000 shares authorized at September 30, 2010 and
June 30, 2010, respectively; (10 votes per share), 158 issued
and outstanding at September 30, 2010 and June 30, 2010 - -
Class C Common Stock $.0001 par value; 567,000 and 2,000,000
shares authorized at September 30, 2010 and June 30, 2010,
respectively; (25 votes per share), 382,513 issued
and outstanding at September 30, 2010 and June 30, 2010 - -
Paid-in capital in excess of par value 172,568 172,379
Accumulated other comprehensive loss (15) (19)
Accumulated deficit (176,886) (177,271)
Notes receivable from employee stockholders (190) (191)
Treasury stock, at cost - 11,643 shares of common stock
at September 30, 2010 and June 30, 2010 (675) (675)
-------- --------
Total Stockholders' Deficiency (5,197) (5,776)
-------- --------
Total Liabilities and Stockholders' Deficiency $ 21,988 $ 21,629
======== ========
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
FOR THE THREE MONTHS ENDED
SEPTEMBER 30,
--------------------------
2010 2009
REVENUES -------- --------
Product sales - net $ 2,660 $ 1,563
Service and repair fees - net 2,689 2,757
Service and repair fees - related parties - net 55 55
Management and other fees - net 2,088 1,736
Management and other fees - related medical
practices - net 1,193 795
License fees and royalties - 585
-------- --------
Total Revenues - Net 8,685 7,491
-------- --------
COSTS AND EXPENSES
Costs related to product sales 2,506 1,657
Costs related to service and repair fees 665 941
Costs related to service and repair
fees - related parties 14 19
Costs related to management and other fees 1,313 1,268
Costs related to management and other
fees - related medical practices 739 761
Research and development 454 854
Selling, general and administrative 2,383 3,233
Provision for bad debts 176 180
-------- --------
Total Costs and Expenses 8,250 8,913
-------- --------
Income (Loss) From Operations 435 ( 1,422)
Interest Expense ( 94) ( 79)
Interest Expense - Related Parties ( 4) ( 14)
Investment Income 38 87
Interest Income - Related Party 1 4
Other Income 9 33
Loss on Note Receivable - ( 350)
-------- --------
NET INCOME (LOSS) $ 385 $( 1,741)
======== ========
Net Income (Loss) Available to Common Stockholders $ 363 $( 1,741)
======== ========
Basic Net Income (Loss) Per Common Share $ 0.07 $ (0.35)
======== ========
Diluted Net Income (Loss) Per Common Share $ 0.07 $ (0.35)
======== ========
Basic and Diluted Income Per Share - Common C $ 0.02 N/A
======== ========
Weighted Average Basic Shares Outstanding 5,012,245 4,907,942
========= =========
Weighted Average Diluted Shares Outstanding 5,139,749 4,907,942
========= =========